scholarly journals Combined external pelvic chemoradiotherapy and image-guided adaptive brachytherapy in treatment of advanced cervical carcinoma: experience from a single institution

2020 ◽  
Vol 12 (4) ◽  
pp. 356-366
Author(s):  
Sigrid Möller ◽  
Louise Bohr Mordhorst ◽  
Ruth Hermansson ◽  
Leif Karlsson ◽  
Ulf Granlund ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Single Institution ◽  
Image Guided ◽  
Advanced Cervical Carcinoma

Teniposide in recurrent or advanced cervical carcinoma: A phase II trial in patients not previously treated with cytotoxic therapy

1990 ◽  
Vol 37 (2) ◽  
pp. 230-233 ◽  
Author(s):  
Per Pfeiffer ◽  
Søren Cold ◽  
Kamma Bertelsen ◽  
Jytte Panduro ◽  
Erik Sandberg ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cytotoxic Therapy ◽  
Advanced Cervical Carcinoma ◽  
Previously Treated

Enhanced Radiosensitization with Interferon-α-2b and Cisplatin in the Treatment of Locally Advanced Cervical Carcinoma

1997 ◽  
Vol 67 (3) ◽  
pp. 309-315 ◽  
Author(s):  
Richard G. Stock ◽  
Peter Dottino ◽  
T.Scott Jennings ◽  
Mitchell Terk ◽  
J.Keith Dewyngaert ◽  
...  
Keyword(s):  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Interferon Α ◽  
Advanced Cervical Carcinoma

Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

1995 ◽  
Vol 109 (8) ◽  
pp. 744-747 ◽  
Author(s):  
John S. Rubin ◽  
Scott Wadler ◽  
Jonathan J. Baitler ◽  
Hilda Haynes ◽  
Alla Rozenblet ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Phase I ◽  
Cervical Carcinoma ◽  
Locally Advanced ◽  
Hearing Threshold ◽  
High Dose ◽  
High Frequencies ◽  
Advanced Cervical Carcinoma ◽  
Before And After ◽  
Audiologic Testing

AbstractWR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin. which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma. 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes. predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.

Sign in / Sign up

Export Citation Format

Share Document